Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Post-Authorisation Safety Study (PASS) of MOVENTIG® (Naloxegol) Among Patients Aged 18 Years and Older Treated With Opioids Chronically

NCT02813369 is registered in ClinicalTrials.gov with Kyowa Kirin Pharmaceutical Development Ltd as lead sponsor.

NCT NCT02813369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02813369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Post-Authorisation Safety Study (PASS) of MOVENTIG® (Naloxegol) Among Patients Aged 18 Years and Older Treated With Opioids Chronically
Lead sponsor
Kyowa Kirin Pharmaceutical Development Ltd
Phase
Observational
Overall status
Terminated
Start date
September 30, 2016
Completion date
November 30, 2021
Enrollment
10,000 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

opioid induced constipation